Form 8-K - Current report:
SEC Accession No. 0001104659-26-066974
Filing Date
2026-05-27
Accepted
2026-05-27 16:30:41
Documents
12
Period of Report
2026-05-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2615785d1_8k.htm   iXBRL 8-K 32113
  Complete submission text file 0001104659-26-066974.txt   242611

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA limn-20260520.xsd EX-101.SCH 3359
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE limn-20260520_def.xml EX-101.DEF 26585
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE limn-20260520_lab.xml EX-101.LAB 36487
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE limn-20260520_pre.xml EX-101.PRE 25209
15 EXTRACTED XBRL INSTANCE DOCUMENT tm2615785d1_8k_htm.xml XML 4976
Mailing Address 12611 HIDDENCREEK WAY UNIT C CERRITOS CA 90703
Business Address 12611 HIDDENCREEK WAY UNIT C CERRITOS CA 90703 213-273-5453
Liminatus Pharma, Inc. (Filer) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42626 | Film No.: 261026667
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)